BR112019020667A8 - Rna para tratamento de doenças autoimunes - Google Patents

Rna para tratamento de doenças autoimunes

Info

Publication number
BR112019020667A8
BR112019020667A8 BR112019020667A BR112019020667A BR112019020667A8 BR 112019020667 A8 BR112019020667 A8 BR 112019020667A8 BR 112019020667 A BR112019020667 A BR 112019020667A BR 112019020667 A BR112019020667 A BR 112019020667A BR 112019020667 A8 BR112019020667 A8 BR 112019020667A8
Authority
BR
Brazil
Prior art keywords
rna
treatment
autoimmune diseases
autoantigen
development
Prior art date
Application number
BR112019020667A
Other languages
English (en)
Other versions
BR112019020667A2 (pt
Inventor
Sahin Ugur
Kreiter Sebastian
Krienke Christina
PETSCHENKA Jutta
Mareen Kranz Lena
Diken Mustafa
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Biontech Rna Pharmaceuticals Gmbh
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Rna Pharmaceuticals Gmbh, BioNTech SE filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Publication of BR112019020667A2 publication Critical patent/BR112019020667A2/pt
Publication of BR112019020667A8 publication Critical patent/BR112019020667A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A presente invenção refere-se a RNA não imunogênico. Este RNA constitui a base para o desenvolvimento de agentes terapêuticos para indução de tolerância em direção a um autoantígeno e assim, para o tratamento de doenças autoimunes.
BR112019020667A 2017-04-11 2018-04-10 Rna para tratamento de doenças autoimunes BR112019020667A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases
PCT/EP2018/059188 WO2018189193A1 (en) 2017-04-11 2018-04-10 Rna for treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
BR112019020667A2 BR112019020667A2 (pt) 2020-05-05
BR112019020667A8 true BR112019020667A8 (pt) 2022-08-16

Family

ID=58632945

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019020667A BR112019020667A8 (pt) 2017-04-11 2018-04-10 Rna para tratamento de doenças autoimunes

Country Status (22)

Country Link
US (2) US11701413B2 (pt)
EP (2) EP3981424A1 (pt)
JP (3) JP7078641B2 (pt)
KR (2) KR20190134765A (pt)
CN (1) CN110719787B (pt)
AU (1) AU2018253352A1 (pt)
BR (1) BR112019020667A8 (pt)
CA (1) CA3059505A1 (pt)
CY (1) CY1124767T1 (pt)
DK (1) DK3609529T3 (pt)
ES (1) ES2893451T3 (pt)
HR (1) HRP20211559T1 (pt)
HU (1) HUE056871T2 (pt)
IL (2) IL269793B (pt)
LT (1) LT3609529T (pt)
MX (1) MX2019012144A (pt)
PL (1) PL3609529T3 (pt)
PT (1) PT3609529T (pt)
RS (1) RS62582B1 (pt)
SG (2) SG11201909520VA (pt)
SI (1) SI3609529T1 (pt)
WO (2) WO2018188730A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119449A1 (en) * 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
AU2022282551A1 (en) 2021-05-26 2023-12-14 Imcyse Sa Methods of treating or preventing autoimmune diseases
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023131254A1 (zh) * 2022-01-06 2023-07-13 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
CA2783032C (en) * 2009-12-07 2022-08-30 Gary Dahl Rna preparations comprising purified modified rna for reprogramming cells
WO2012154933A1 (en) * 2011-05-10 2012-11-15 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
CN103998055B (zh) * 2011-09-30 2017-10-24 北京艾棣维欣生物技术有限公司 预防和治疗自身免疫性疾病的联合促进剂、抗原和dna疫苗
DK3421601T3 (da) * 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN106395552B (zh) * 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯系统导轨组件
JP7078812B2 (ja) * 2015-08-28 2022-06-01 バイオンテック・エスイー Ｒｎａの免疫原性を低減するための方法
MD3445850T2 (ro) 2016-04-22 2022-01-31 BioNTech SE Metode de obținere a ARN monocatenar

Also Published As

Publication number Publication date
WO2018189193A1 (en) 2018-10-18
BR112019020667A2 (pt) 2020-05-05
CN110719787A (zh) 2020-01-21
RU2019135808A3 (pt) 2021-08-10
IL290980A (en) 2022-05-01
CN110719787B (zh) 2024-03-15
JP2020516658A (ja) 2020-06-11
EP3609529A1 (en) 2020-02-19
JP2022110127A (ja) 2022-07-28
WO2018188730A1 (en) 2018-10-18
EP3981424A1 (en) 2022-04-13
US20200061166A1 (en) 2020-02-27
RS62582B1 (sr) 2021-12-31
JP7444924B2 (ja) 2024-03-06
CY1124767T1 (el) 2022-11-25
PT3609529T (pt) 2021-10-14
CA3059505A1 (en) 2018-10-18
US11701413B2 (en) 2023-07-18
KR20240042138A (ko) 2024-04-01
JP7078641B2 (ja) 2022-05-31
DK3609529T3 (da) 2021-10-11
US20230330198A1 (en) 2023-10-19
HUE056871T2 (hu) 2022-04-28
RU2019135808A (ru) 2021-05-11
KR20190134765A (ko) 2019-12-04
SG10202111163VA (en) 2021-11-29
IL269793B (en) 2022-04-01
SI3609529T1 (sl) 2021-11-30
LT3609529T (lt) 2021-10-25
HRP20211559T1 (hr) 2022-01-21
IL269793A (en) 2019-11-28
EP3609529B1 (en) 2021-09-08
ES2893451T3 (es) 2022-02-09
PL3609529T3 (pl) 2021-12-13
MX2019012144A (es) 2019-11-21
AU2018253352A1 (en) 2019-10-17
JP2024059794A (ja) 2024-05-01
SG11201909520VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
BR112019020667A8 (pt) Rna para tratamento de doenças autoimunes
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
EA201791736A1 (ru) Комбинированная терапия для лечения рака
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
CY1123116T1 (el) Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112018070255A2 (pt) reprogramação cardíaca direta melhorada.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; BIONTECH SE (DE)